NCT03564301 is a Phase 4 clinical trial of Metronidazole 250 MG in Peri-Implantitis, sponsored by Juan Blanco Carrión.

Who is sponsoring NCT03564301?

NCT03564301 is sponsored by Juan Blanco Carrión.

What drugs are being tested in NCT03564301?

Interventions in NCT03564301: Placebo oral capsule, Metronidazole 250 MG.

What condition does NCT03564301 study?

NCT03564301 studies Peri-Implantitis.

Is NCT03564301 still recruiting?

NCT03564301 is currently completed. Last updated 28 April 2021.

Last reviewed 2021-04-28 · How we verify

NCT03564301

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metronidazole as an Adjunct of Non- Surgical Treatment of Peri-implantitis

Completed Phase 4 Last updated 28 April 2021

What this trial tests

Phase 4 trial testing Placebo oral capsule in Peri-Implantitis in 20 participants. Completed in 22 December 2020.

Timeline

3 March 2018

Primary endpoint
1 March 2020

22 December 2020

Quick facts

Lead sponsor	Juan Blanco Carrión
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	20
Start date	3 March 2018
Primary completion	1 March 2020
Estimated completion	22 December 2020
Sites	1 location across Spain

Drugs / interventions tested

Placebo oral capsule
Metronidazole 250 MG

Conditions studied

Peri-Implantitis — all drugs for Peri-Implantitis →

Sponsor

Juan Blanco Carrión

Who can join

18 and older, any sex, with Peri-Implantitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The use of systemic antibiotics as and adjunct to non-surgical peri-implant therapy may be an improvement in comparison to these therapies alone. The primary objective is the evaluation of significant changes in probing pocket depth between non-surgical with or without antibiotics. This is a controlled-placebo clinical trial design. Patients with osseointegrated oral implants will be selected and recruited from a university clinic. Oral hygiene instruction and non-surgical debridement at implants will be provided with ultrasonic devices and immediately after, patients will be prescribed: Group Control: A placebo with the same characteristics as the antibiotic Group Test: Systemic antibiotics (Metronidazole 250mg, 2 capsules three times a day, for 7 days Three and six months after non-surgical treatment, clinical parameters will be registered and radiographs compared using reproducible landmarks. Any adverse event will be also recorded.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Adjunctive benefits of systemic metronidazole on non-surgical treatment of peri-implantitis. A randomized placebo-controlled clinical trial.
Blanco C, Pico A, Dopico J, Gándara P, et al · · 2022 · cited 45× · PMID 34713471 · DOI 10.1111/jcpe.13564
The systemic impact of non-surgical treatment of peri-implantitis with or without adjunctive systemic metronidazole: Secondary analysis of a randomized clinical trial.
Liñares A, Dopico J, Blanco C, Pico A, et al · · 2024 · cited 1× · PMID 39093380 · DOI 10.1111/clr.14339

Verify or expand the search:

Other trials of Metronidazole 250 MG

Trials testing the same drug.

NCT06509139 — Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males · Phase 4 · enrolling by invitation
NCT04527055 — The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication · Phase 4 · enrolling by invitation

Other recruiting trials for Peri-Implantitis

Currently open trials in the same condition.

NCT07012915 — Immunological-Clinical Evaluation of the Etiopathogenesis of Peri-Implantitis · NA · recruiting
NCT06679283 — Surgical Treatment of Peri-implantitis With Adjunctive Application of Platelet Rich Fibrin (PRF) · NA · recruiting
NCT06017817 — Antibacterial Photodynamic Therapy in the Management of Peri-implantitis · NA · recruiting
NCT06364982 — Distance Between Dental Implants as a Risk Indicator for Peri-implant Disease. · recruiting
NCT06288919 — Erythritol vs Ultrasonic Scaler Prophylaxis Systems on Dental Implants With Crowns Made by Different Materials · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03564301 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Juan Blanco Carrión
Last refreshed: 28 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03564301.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing